A phase IIIb study of intermittent versus continuous hormone deprivation treatment with ELIGARD [leuprorelin] 22.5 mg 3-Month Depot in Subjects With Relapsing and Locally Advanced Prostate Cancer Who Are Responsive to Such Therapy.

Trial Profile

A phase IIIb study of intermittent versus continuous hormone deprivation treatment with ELIGARD [leuprorelin] 22.5 mg 3-Month Depot in Subjects With Relapsing and Locally Advanced Prostate Cancer Who Are Responsive to Such Therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Feb 2017

At a glance

  • Drugs Leuprorelin (Primary)
  • Indications Prostate cancer
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms ICELAND
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 Oct 2016 Results of a post-hoc analysis assessing clinical outcomes and testosterone levels following continuous androgen deprivation (CAD) were presented at the 41st European Society for Medical Oncology Congress
    • 19 May 2015 Results presented at the 110th Annual Meeting of the American Urological Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top